Monday, February 7, 2011

Tautomycetin Antibiotic Offers Potential for Anti-Cancer Activity.....

Tautomycetin-antibiotic((1R*,2S*)-16-Ethyl-3,7-dihydroxy-1, 2,6,10,12-pentamethyl-5,14-dioxo- 15,17-octadecadienyl 2,5-dihydro-β-hydroxy-4-methyl-2,5-dioxo-3-furanpro panoic acid estersee structure) known for its immunosuppressive functions could also point the way to the development of new anti-cancer agents, researchers at the Indiana University School of Medicine have reported. 

Study determined that the compound, tautomycetin, targets an enzyme called SHP2, which plays an important role in cell activities such as proliferation and differentiation. Interestingly, SHP2 mutations are also known to cause several types of leukemia and solid tumors.

The finding is encouraging because SHP2 is a member of a large family of enzymes called protein tyrosine phosphotases (PTPs), which are important in the signaling processes that control all essential cellular functions. Dysregulation of PTP activity has been linked to several human diseases, including cancer, diabetes, and immune dysfunctions. But their makeup has made it difficult to find potential drugs to act on them.

Authors conclude that,  the  research will serve as a foundation for the development of therapeutic agents for a large family of protein tyrosine phosphotase targets…..

Sijiu Liu, Zhihong Yu,

No comments: